

Oxlumo

CareFirst Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. Please respond below and fax this form to CVS Caremark toll-free at 1-855-330-1720. If you have questions regarding the prior authorization, please contact CVS Caremark at 1-888-877-0518. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to <u>do_not_call@cvscaremark.com</u>. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name:	Date:
Patient's ID:	Patient's Date of Birth:
Physician's Name:	
Specialty:	NPI#:
Physician Office Telephone:	Physician Office Fax:
Referring Provider Info:	sting Provider
Name:	NPI#:
Fax:	Phone:
Rendering Provider Info: 🗖 Same as Refer	ring Provider 🖵 Same as Requesting Provider
Name:	NPI#:
Fax:	Phone:

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

Required Demographic Information:

Patient Weight:	kg
Patient Height:	ст

What is the ICD-10 code?

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. CareFirst Oxlumo C26811-A SGM SOC 5406-A - 08/2024.

CVS Caremark Specialty Pharmacy • 2211 Sanders Road NBT-6 • Northbrook, IL 60062

Phone: 1-888-877-0518 • Fax: 1-855-330-1720 • www.caremark.com

Site of Service Questions:

- A. Where will this drug be administered?
 - Ambulatory surgical, *skip to Clinical Criteria Questions*
 - □ Home infusion, *skip to Clinical Criteria Questions*
 - Gold Off-campus Outpatient Hospital, Continue to B
 - □ On-campus Outpatient Hospital, *Continue to B*
 - Depresentation Physician office, skip to Clinical Criteria Questions
 - □ Pharmacy, *skip to Clinical Criteria Questions*
- B. Is the patient less than 14 years of age?
 □ Yes, *skip to Clinical Criteria Questions*□ No, *Continue to C*
- *C.* Is this request to continue previously established treatment with the requested medication? *Action Required: If No, please attach supporting clinical documentation.*

 \Box Yes - This is a continuation of an existing treatment., *Continue to D*

□ No - This is a new therapy request (patient has not received requested medication in the last 6 months)., *skip to Clinical Criteria Questions*

D. Has the patient experienced an adverse event with the requested product that has not responded to conventional interventions (eg acetaminophen, steroids, diphenhydramine, fluids, or other pre-medications) or a severe adverse event (anaphylaxis, anaphylactoid reactions, myocardial infarction, thromboembolism, or seizures) during or immediately after an administration? *ACTION REQUIRED: If Yes, please attach supporting clinical documentation.*

□ Yes, *skip to Clinical Criteria Questions* □ No, *Continue to E*

E. Is the patient medically unstable which may include respiratory, cardiovascular, or renal conditions that may limit the member's ability to tolerate a large volume or load or predispose the member to a severe adverse event that cannot be managed in an alternate setting without appropriate medical personnel and equipment?

ACTION REQUIRED: If Yes, please attach supporting clinical documentation.
□ Yes, skip to Clinical Criteria Questions
□ No, Continue to F

F. Does the patient have significant behavioral issues and/or physical or cognitive impairment that would impact the safety of the infusion therapy AND the patient does not have access to a caregiver? *ACTION REQUIRED: If Yes, please attach supporting clinical documentation.*

□ Yes, *skip to Clinical Criteria Questions* □ No, *Continue to G*

G. Are *all* alternative infusion sites (pharmacy, physician office, ambulatory care, etc.) greater than 30 miles from the patient's home? *ACTION REQUIRED: If Yes, please attach supporting documentation*.
□ Yes, *continue to Clinical Criteria Questions*□ Note the formula of the patient of th

□ No, continue to Clinical Criteria Questions

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. CareFirst Oxlumo C26811-A SGM SOC 5406-A - 08/2024.

CVS Caremark Specialty Pharmacy • 2211 Sanders Road NBT-6 • Northbrook, IL 60062

Phone: 1-888-877-0518 • Fax: 1-855-330-1720 • www.caremark.com

Clinical Criteria Questions:

1. What is the diagnosis?

□ Primary hyperoxaluria type 1 (PH1), Continue to #2

□ Other, *Continue to #2*

2. Was the patient's diagnosis confirmed by either of the following: A) Molecular genetic test showing a mutation in the alanine: glyoxylate aminotransferase (AGXT) gene, B) Liver enzyme analysis demonstrating absent or significantly reduced alanine: glyoxylate aminotransferase (AGT) activity? *ACTION REQUIRED*: *If yes, attach supporting chart note(s) for molecular genetic tests showing a mutation in the alanine: glyoxylate aminotransferase (AGXT) gene or a liver enzyme analysis demonstrating absent or significantly reduced alanine: glyoxylate aminotransferase (AGT) activity*

□ Yes, Continue to #3

□ No, Continue to #3

3. Is the requested medication prescribed by or in consultation with a nephrologist, gastroenterologist, geneticist, urologist, or physician specializing in the treatment of hyperoxaluria?

- □ Yes, *Continue to #4*
- □ No, *Continue to #4*

4. Is the patient a recipient of a liver transplant?

□ Yes, Continue to #5

□ No, Continue to #5

5. What is the patient's age?

- □ 18 years of age or older, *Continue to #9*
- □ Less than 18 years of age, *Continue to #6*

6. What is the patient's weight?

- □ Less than 10kg, *Continue to* #7
- \Box 10 to less than 20kg, *Continue to #8*
- Greater than or equal to 20kg, *Continue to #9*

7. Does the prescribed dose exceed either of the following?

- Loading dose: 6 mg/kg/dose SUBQ once monthly for 3 doses.
- Maintenance dosage: 3 mg/kg/dose SUBQ once monthly; begin 1 month after last loading dose.

 \square Yes, Continue to #10

□ No, *Continue to #10*

8. Does the prescribed dose exceed either of the following?

- Loading dose: 6 mg/kg/dose SUBQ once monthly for 3 doses.
- Maintenance dosage: 6 mg/kg/dose SUBQ every 3 months; begin 1 month after last loading dose.
- \Box Yes. Continue to #10

 \square No, Continue to #10

9. Does the prescribed dose exceed either of the following?

- Loading dose: 3 mg/kg/dose SUBQ once monthly for 3 doses.
- Maintenance dosage: 3 mg/kg/dose SUBQ every 3 months; begin 1 month after last loading dose.
- □ Yes, Continue to #10
- □ No, Continue to #10

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. CareFirst Oxlumo C26811-A SGM SOC 5406-A - 08/2024.

CVS Caremark Specialty Pharmacy • 2211 Sanders Road NBT-6 • Northbrook, IL 60062

Phone: 1-888-877-0518 • Fax: 1-855-330-1720 • www.caremark.com

10. IS this request for continuation of therapy?

□ Yes, Continue to #11

□ No, *No Further Questions*

11. Has the patient's urinary and/or plasma oxalate decreased or normalized since initiation of therapy?

Tes, No Further Questions

□ No, *No Further Questions*

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.

Prescriber or Authorized Signature

Х

Date (mm/dd/yy)

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720 Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. CareFirst Oxlumo C26811-A SGM SOC 5406-A – 08/2024. CVS Caremark Specialty Pharmacy • 2211 Sanders Road NBT-6 • Northbrook, IL 60062

Phone: 1-888-877-0518 • Fax: 1-855-330-1720 • www.caremark.com

Page 4 of 4